<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Front Pediatr</journal-id>
<journal-id journal-id-type="iso-abbrev">Front Pediatr</journal-id>
<journal-id journal-id-type="publisher-id">Front. Pediatr.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Pediatrics</journal-title>
</journal-title-group>
<issn pub-type="epub">2296-2360</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30619789</article-id>
<article-id pub-id-type="pmc">6299043</article-id>
<article-id pub-id-type="doi">10.3389/fped.2018.00394</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pediatrics</subject>
<subj-group>
<subject>Mini Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Modeling Inflammation in Autism Spectrum Disorders Using Stem Cells</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Freitas</surname>
<given-names>Beatriz C.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/652626/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mei</surname>
<given-names>Arianna</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/645177/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mendes</surname>
<given-names>Ana Paula D.</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/652647/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Beltrão-Braga</surname>
<given-names>Patricia C. B.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/365908/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Marchetto</surname>
<given-names>Maria Carolina</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="corresp" rid="c001">
<sup>*</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/343690/overview" xlink:type="simple"></uri>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Laboratory of Disease Modeling, Department of Microbiology, Institute of Biomedical Sciences, University of São Paulo</institution>, <addr-line>São Paulo</addr-line>, <country>Brazil</country></aff>
<aff id="aff2"><sup>2</sup><institution>Laboratory of Genetics, The Salk Institute</institution>, <addr-line>La Jolla, CA</addr-line>, <country>United States</country></aff>
<aff id="aff3"><sup>3</sup><institution>School of Arts, Sciences and Humanities, University of São Paulo</institution>, <addr-line>São Paulo</addr-line>, <country>Brazil</country></aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Sofia Beatriz Lizarraga, University of South Carolina, United States</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Steven Sloan, Emory University, United States; Filippo M. Santorelli, Fondazione Stella Maris (IRCCS), Italy</p>
</fn>
<corresp id="c001">*Correspondence: Maria Carolina Marchetto <email>marchetto@salk.edu</email></corresp>
<fn fn-type="other" id="fn001">
<p>This article was submitted to Pediatric Neurology, a section of the journal Frontiers in Pediatrics</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>12</day>
<month>12</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="collection">
<year>2018</year>
</pub-date>
<volume>6</volume>
<elocation-id>394</elocation-id>
<history>
<date date-type="received">
<day>25</day>
<month>9</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>29</day>
<month>11</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2018 Freitas, Mei, Mendes, Beltrão-Braga and Marchetto.</copyright-statement>
<copyright-year>2018</copyright-year>
<copyright-holder>Freitas, Mei, Mendes, Beltrão-Braga and Marchetto</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<p>Recent reports show an increase in the incidence of Autism Spectrum Disorders (ASD) to 1 in every 59 children up to 8 years old in 11 states in North America. Induced pluripotent stem cell (iPSC) technology offers a groundbreaking platform for the study of polygenic neurodevelopmental disorders in live cells. Robust inflammation states and immune system dysfunctions are associated with ASD and several cell types participate on triggering and sustaining these processes. In this review, we will examine the contribution of neuroinflammation to the development of autistic features and discuss potential therapeutic approaches. We will review the available tools, emphasizing stem cell modeling as a technology to investigate the various molecular pathways and different cell types involved in the process of neuroinflammation in ASD.</p>
</abstract>
<kwd-group>
<kwd>autism spectrum disorder (ASD)</kwd>
<kwd>disease modeling</kwd>
<kwd>neuroinflammation</kwd>
<kwd>neurodevelopmental disorders</kwd>
<kwd>induced pluripotent stem (iPS) cells</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source id="cn001">National Institutes of Health<named-content content-type="fundref-id">10.13039/100000002</named-content></funding-source>
</award-group>
</funding-group>
<counts>
<fig-count count="1"></fig-count>
<table-count count="0"></table-count>
<equation-count count="0"></equation-count>
<ref-count count="95"></ref-count>
<page-count count="8"></page-count>
<word-count count="6767"></word-count>
</counts>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<title>Introduction</title>
<p>Autism Spectrum Disorder (ASD) is a lifelong neurodevelopmental disorder characterized by the impairment of social abilities and cognitive functions that can manifest cortical disorganization or neuroinflammation states (<xref ref-type="bibr" rid="B1">1</xref>). As a complex polygenic disorder with several degrees of severity, the causes of ASD are not completely elucidated. Autism can be of unknown gene etiology (idiopathic) (<xref ref-type="bibr" rid="B2">2</xref>) or a specific syndromic disorder, such as Rett Syndrome or Fragile X where single gene mutations can manifest ASD features. Elucidating the etiology of ASD could help understanding the increase in incidence (<xref ref-type="bibr" rid="B3">3</xref>) and drive research efforts toward novel therapeutic approaches.</p>
<p>Earlier recognition of ASD symptoms results in better patient prognosis after behavioral therapy (<xref ref-type="bibr" rid="B4">4</xref>). Cortical changes, such as increased head circumference and brain volume reported for a subset of ASD toddlers, allow for potential clinical diagnosis before 1 year of age, especially when aligned with a genetic investigation of known genes that play a role in neural development (<xref ref-type="bibr" rid="B4">4</xref>). Sequencing of whole genomes of families where the proband was affected with ASD uncovered rare <italic>de novo</italic> mutations on genes that segregate with ASD (<xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B6">6</xref>). These mutations are heterogeneous and only account for &lt; 1% of ASD cases (<xref ref-type="bibr" rid="B7">7</xref>), highlighting the polygenic nature of ASD. A subset of the genes identified in ASD (<italic>FMR1, CHD8, DYRK1, NLGN3, PTEN</italic>) and 16p11 deletion, are likely involved in brain volume changes and neural connectivity, and its particular function can be studied in animal models and genetically engineered human cells (<xref ref-type="bibr" rid="B8">8</xref>). The majority of idiopathic ASD cases lack a known culprit gene(s), with phenotypes ranging across a wide pathological spectrum. In those cases, differential scientific approaches, such as the use of stem cell modeling and comprehensive <italic>in silico</italic> data analysis are required. Furthermore, twin studies suggest that hereditary mechanisms and environment also play a role in ASD during mid-fetal brain development (<xref ref-type="bibr" rid="B9">9</xref>).</p>
<p>Several studies report immune system misbalances in ASD (<xref ref-type="bibr" rid="B10">10</xref>–<xref ref-type="bibr" rid="B12">12</xref>). Particularly, immune system involvement has been associated with three major circumstances: 1-<italic>specific immune-related genes</italic>, 2-<italic>maternal risk factor</italic> (ex. gestational diabetes and/or obesity), and 3-<italic>maternal immune activation (MIA) during pregnancy</italic> (ex. viral infection) (<xref ref-type="bibr" rid="B13">13</xref>). A common feature associated with these three scenarios is the altered number of synapses in the fetus leading to deficits during neurodevelopment.</p>
<p>Global expression differences in genes related to inflammatory response in ASD individuals were reported by several studies (<xref ref-type="bibr" rid="B14">14</xref>–<xref ref-type="bibr" rid="B16">16</xref>). Transcriptome analysis of ASD post-mortem brains revealed a close association between ASD and the genes related to glial cell activation and genes belonging to immune and inflammatory categories (<xref ref-type="bibr" rid="B17">17</xref>). The <italic>MET</italic> gene (proto-oncogene receptor, tyrosine kinase) known to regulate cell immune functions amongst other roles (<xref ref-type="bibr" rid="B18">18</xref>) is the immune gene most closely associated with ASD (<xref ref-type="bibr" rid="B19">19</xref>), coding for a receptor that binds to hepatocyte growth factor (HGF). Single nucleotide polymorphisms (SNPs) were described at high incidence in ASD and reduced expression of aberrant <italic>MET</italic> was shown in post-mortem brains of ASD individuals (<xref ref-type="bibr" rid="B20">20</xref>). SNPs generating deficiencies of the complement component 4 (C4) gene function, located in the MHC region, have also been associated with ASD (<xref ref-type="bibr" rid="B21">21</xref>, <xref ref-type="bibr" rid="B22">22</xref>). Additional components of the complement cascade (<italic>C3, Masp1, Masp2, C3aR</italic>, and <italic>C5aR</italic>) participate in microglial function and neuronal migration and are potentially implicated in altered cortical development in ASD (<xref ref-type="bibr" rid="B23">23</xref>, <xref ref-type="bibr" rid="B24">24</xref>).</p>
<p>Maternal history of increased inflammation, such as development of eczema, psoriasis, and asthma was correlated with a 20–40% increased risk for both ASD and other developmental disorders (<xref ref-type="bibr" rid="B25">25</xref>). Other risk factors apart from the immune deficiencies mentioned are gestational diabetes, obesity, and aging that were linked to an increased chance of a child to developing ASD (<xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B27">27</xref>). Lastly, acquiring MIA due to a viral infection during pregnancy shows evidence of an additional increased risk for developing ASD (<xref ref-type="bibr" rid="B28">28</xref>).</p>
<p>Anomalies in immune signaling pathways are reported for ASD (<xref ref-type="bibr" rid="B29">29</xref>). Specifically, altered cytokine profiles and immunoglobulin G (IgG) levels were associated with intensified cellular immunity and general amplified neuroinflammation. Detection of misbalanced expression of inflammatory cytokines (IL-6, TNFα, TGFβ, IL-17, and IL-2) was reported in ASD patients' blood (<xref ref-type="bibr" rid="B30">30</xref>). Unfortunately, due to the complexity of this disorder, none of these alterations resulted in a biomarker panel for predicting ASD prognosis. In this review we will highlight the role of inflammation in ASD focusing on the data obtained from stem cell modeling.</p>
</sec>
<sec id="s2">
<title>Stem Cell Models in Autism Spectrum Disorder (ASD)</title>
<p>Neurodevelopmental polygenic disorders, such as ASD are notably attractive for the application of stem cell technology as early hallmarks of neuronal development can be dissected <italic>in vitro</italic> and patients' unique genetic background can be recapitulated (<xref ref-type="bibr" rid="B31">31</xref>). Embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) have the ability to generate functional human neuronal and glial cells <italic>in vitro</italic>, and can self-organize into 3D brain organoid cultures (<xref ref-type="bibr" rid="B32">32</xref>) (Figure <xref ref-type="fig" rid="F1">1</xref>). iPSCs recapitulate aspects of neuronal development process while preserving the genetic background from ASD patients and thus are more frequently used to model idiopathic conditions. Additionally, isogenic lines can be developed to understand the impact of a specific mutation in different genetic backgrounds. While gene-editing technology is ideal for understanding the function of a single gene, the results are not always generalizable to the autistic condition. In that case, having iPSC lines from a cohort of patients with a specific endophenotype (ex. macrocephaly) can be informative for understanding ASD <italic>in vitro</italic> phenotypes. Unfortunately for idiopathic polygenic ASD, isogenic lines are not always a viable option.</p>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption>
<p><bold>(A)</bold> Syndromic ASD historically has been studied using rodent models leading to drug discovery for therapeutic approaches (red arrow). <bold>(B)</bold> With iPSC modeling both syndromic and idiopathic ASD forms can be investigated in different cell types from the nervous system, or in a complex co-culture model system and used for high-throughput screening (HTS). Validation of target compounds can be performed on iPSC-derived and rodent models, providing therapeutic possibilities as early as during brain development (red arrows). Figure created in the <italic>Mind the Graph</italic> platform with subscription purchased by the authors.</p>
</caption>
<graphic xlink:href="fped-06-00394-g0001"></graphic>
</fig>
</sec>
<sec id="s3">
<title>Idiopathic ASD</title>
<p>Despite being a polygenic disorder, there appears to be converging phenotypes in ASD. A common finding from ASD studies reporting the generation of iPSC-derived neurons from syndromic or idiopathic ASD is <italic>altered synaptic activity</italic> (<xref ref-type="bibr" rid="B33">33</xref>–<xref ref-type="bibr" rid="B41">41</xref>). iPSC technology allows for the interrogation of the specific neurobiological foundations underlying common synaptic defects and synaptopathy in the context of neurodevelopmental disorders such ASD (<xref ref-type="bibr" rid="B42">42</xref>).</p>
<p>Aiming to recapitulate clinical post-mortem findings in neurons, one group using gene expression analyses on three-dimensional cultures derived from iPSCs showed up-regulation of genes involved in cell proliferation, neuronal differentiation, and synaptic formation (<xref ref-type="bibr" rid="B34">34</xref>). In this study, Mariani et al. (<xref ref-type="bibr" rid="B34">34</xref>) suggested that overexpression of the gene <italic>FOXG1</italic> can generate an overproduction of GABAergic neurons, which can cause increase of brain volume and imbalance of excitation and inhibition systems in the developing cortex in ASD.</p>
<p>Increased proliferation of iPSC-derived neural progenitors from ASD individuals with enlarged brains was also reported by Marchetto et al. (<xref ref-type="bibr" rid="B35">35</xref>). Importantly, the authors observed a significant correlation between ASD patients' brain volumes <italic>in vivo</italic> and cell proliferation rates <italic>in vitro</italic>, indicating that iPSC-derived neural cells can be used as a proxy to infer specific patients' metrics (i.e., brain volume). Marchetto et al. (<xref ref-type="bibr" rid="B35">35</xref>) also showed a significant reduction in the density of excitatory synapses in ASD iPSC-derived neurons and decreased neuronal bursting. To date, these findings suggest that despite the overgrowth of the brain size in these young children, their neurons are immature or unhealthy.</p>
<p>Though neuronal phenotypes have been explored in more depth in ASD; glial cells play an important role in the disease as well. A recent study using iPSC-derived neurons and iPSC-derived astrocytes from idiopathic ASD individuals demonstrated that ASD astrocytes influence neuronal morphology and function, evidenced by co-culture experiments (<xref ref-type="bibr" rid="B43">43</xref>). Remarkably, when astrocytes from neurotypical individuals were co-cultured with ASD neurons they improved morphological and functional features that were not observed when ASD neurons were co-cultured with ASD astrocytes. The researchers identified interleukin-6 (IL-6) as a key cytokine responsible for the effect on neuronal activity by showing synaptogenesis recovery in ASD neurons after blocking IL-6 release in ASD astrocytes. The researchers also hypothesized that an increased expression of IL-6 in ASD astrocytes might be one of the triggers of the observed neuronal defects (<xref ref-type="bibr" rid="B43">43</xref>). Interestingly, elevated levels of IL-6, along with other inflammatory cytokines, were reported in the brains and blood of autistic subjects and IL-6 has been found to be a key mediator in MIA models (<xref ref-type="bibr" rid="B30">30</xref>, <xref ref-type="bibr" rid="B44">44</xref>, <xref ref-type="bibr" rid="B45">45</xref>).</p>
</sec>
<sec id="s4">
<title>Inflammation and Syndromic ASD</title>
<sec>
<title>RETT Syndrome (RTT)</title>
<p>RTT is a monogenetic progressive neurologic disorder that shares proposed mechanistic and core symptoms with ASD, with mutations in the X-linked gene <italic>MeCP2</italic> occurring in ~90% of patients with RTT (<xref ref-type="bibr" rid="B46">46</xref>–<xref ref-type="bibr" rid="B48">48</xref>). RTT patients are predominantly female, as affected male patients are rare, and those who survive usually die at early ages (<xref ref-type="bibr" rid="B49">49</xref>–<xref ref-type="bibr" rid="B51">51</xref>). RTT patients have progressive neurological abnormalities starting at 6–18 months after birth. Following a period of progressive neurological damage there is deceleration of head growth, severe motor abnormalities, and loss of language skills. Along with the RTT onset of development stagnation comes impaired motor function, stereotypic hand wringing, hypotonia, seizures, autistic behavior, encephalopathy, and respiratory dysfunction (<xref ref-type="bibr" rid="B46">46</xref>, <xref ref-type="bibr" rid="B49">49</xref>). Amir et al. identified mutations in methyl CpG binding protein 2 (<italic>MeCP2</italic>) as the primary genetic cause of RTT (<xref ref-type="bibr" rid="B47">47</xref>) and Chahrour et al. showed that MeCP2 binding can both repress and activate transcription (<xref ref-type="bibr" rid="B52">52</xref>).</p>
<p>Reduced MeCP2 expression is also found in forebrain post-mortem tissue from idiopathic ASD individuals, suggesting similar epigenetic dysregulation in some cases of idiopathic ASD and RTT (<xref ref-type="bibr" rid="B48">48</xref>). Human iPSC-derived neural cells from RTT patients show fewer synapses, reduced soma size and dendritic spine density, altered calcium signaling and decreased spontaneous excitatory post-synaptic currents (<xref ref-type="bibr" rid="B33">33</xref>, <xref ref-type="bibr" rid="B46">46</xref>). Marchetto et al. showed rescue in synapses phenotype of RTT after treatment with IGF-1 (Insulin Growth Factor Like-1) compound, which is now in clinical trials for RTT (<xref ref-type="bibr" rid="B33">33</xref>). Increased dosage of MeCP2 protein also results in severe neurodevelopmental delay with epilepsy and autistic behavior. Interestingly, iPSC-derived neurons from patients with the <italic>MECP2</italic> duplication syndrome show increased synaptogenesis and dendritic complexity resulting on abnormal network synchronization compared to controls (<xref ref-type="bibr" rid="B37">37</xref>). These results indicate that <italic>MECP2</italic> gene dosage is critical for proper human neurodevelopment.</p>
<p>Neurons were thought to be the most relevant cell type for RTT pathology due to the high expression levels of MeCP2 protein in these cells. Based on previous data showing the non-cell autonomous effect in rodents (<xref ref-type="bibr" rid="B53">53</xref>), a group in 2014 was able to confirm the negative effect of MeCP2-mutant astrocytes in neuronal morphology using iPSCs. Furthermore, IGF-1 and GPE (IGF-1 cleaved peptide) was used to partially rescue the neuronal deficits caused by mutant astrocytes (<xref ref-type="bibr" rid="B54">54</xref>). To date, the direct role of RTT-derived astrocytes in inflammation has not been extensively explored.</p>
<p>Several studies demonstrated that the immune system is involved in RTT in early life. Microglia activation and/or proliferation and defective BDNF signaling is described in RTT (<xref ref-type="bibr" rid="B55">55</xref>). Maezawa et al. proposed that RTT resting microglia are sensitive to both immunological stimuli and neuronal/astrocytic signals causing neuroinflammation and, consequently, affecting brain development (<xref ref-type="bibr" rid="B56">56</xref>, <xref ref-type="bibr" rid="B57">57</xref>).</p>
</sec>
<sec>
<title>Cyclin-Dependent Kinase-Like 5 Disorder (CDKL-5)</title>
<p>CDKL-5 is a kinase protein highly expressed in neurons, but its specific function inside the cell is poorly known (<xref ref-type="bibr" rid="B58">58</xref>). Mutations in X-linked <italic>CDKL5</italic> gene have been identified in the early onset seizures variant of RTT and male X-linked epileptic encephalopathy. CDKL5 expression is present in neurons suggesting an important role in neuronal development. In certain brain regions, MeCP2 protein can regulate the expression of <italic>CDKL5</italic> gene and in turn CDKL5 can phosphorylate MeCP2. Downregulation of CDKL5 expression inhibits neurite outgrowth and maturation of the neuronal network in rodents (<xref ref-type="bibr" rid="B59">59</xref>). iPSC-derived neurons from patients with CDKL5 mutations exhibit aberrant dendritic spines, suggesting a common function of CDKL5 in mice and humans (<xref ref-type="bibr" rid="B58">58</xref>, <xref ref-type="bibr" rid="B60">60</xref>).</p>
<p>The immune system misbalance in Rett syndrome (RTT) can be explained in part by impaired regulation of the inflammatory system. In rodent models MeCP2 regulates gene expression in microglia and macrophage (<xref ref-type="bibr" rid="B61">61</xref>). Leoncini et al. (<xref ref-type="bibr" rid="B62">62</xref>) showed that cytokine levels of RTT patients are misregulated in the blood and that there are differences in cytokine profiling depending on the RTT mutation (<italic>MECP2</italic> vs. <italic>CDKL5</italic>). The researchers also pointed out that omega-3 polyunsaturated fatty acids (PUFAs) partially counterbalanced the cytokine changes and the aberrant redox homeostasis and ameliorated the inflammatory status (<xref ref-type="bibr" rid="B62">62</xref>).</p>
</sec>
<sec>
<title>Fragile X Syndrome (FXS)</title>
<p>Patients with FXS show intellectual disability, hyperactivity and a range of autistic-like behaviors. FXS is characterized by the absence of expression of the fragile X mental retardation 1 (<italic>FMR1</italic>) gene due to CGG trinucleotide repeat expansion in the 5′ untranslated region of <italic>FMR1</italic>. This aberrant expression leads to hypermethylation and gene silencing, leading to the decrease or absence of FMRP (fragile X mental retardation protein) (<xref ref-type="bibr" rid="B46">46</xref>, <xref ref-type="bibr" rid="B63">63</xref>).</p>
<p>FMRP is a selective RNA-binding protein that regulates the translation of many genes at synaptic sites. It was shown that the lack of FMRP leads to the excess and dysregulation of mRNAs translation, which leads to alterations in the synapse function, increased numbers of spines and neuronal overexcitability (<xref ref-type="bibr" rid="B64">64</xref>). A recent study using a Drosophila Fragile-X model showed phagocytosis defects in innate immune cells (<xref ref-type="bibr" rid="B65">65</xref>). Loss of <italic>FMR1</italic> also causes aberrant differentiation in human iPSC-derived neural progenitor cells, particularly a marked induction of the astrocyte marker glial fibrillary acidic protein (GFAP) (<xref ref-type="bibr" rid="B66">66</xref>). In parallel, research also shows increased astrocyte activation in <italic>FMR1</italic> knockout mouse cerebellum (<xref ref-type="bibr" rid="B67">67</xref>), indicating a possible increase in inflammation on both human and mouse models. Although cytokine imbalance was seen with increased IL-6 levels in mouse models (<xref ref-type="bibr" rid="B68">68</xref>), no iPSC-derived study has recapitulated these glial findings <italic>in vitro</italic>. Using ASD and Fragile-X iPSC-derived neurons, a study compared the molecular pathways between these two disorders by global gene expression and DNA methylation profiling, and identified several cytokine molecules, BMP7, and HLA-related abnormalities with aberrant FMRP1 expression (<xref ref-type="bibr" rid="B69">69</xref>).</p>
</sec>
</sec>
<sec id="s5">
<title>Animal Models used for ASD</title>
<p>Mouse modeling is a crucial tool for autism spectrum studies with the generation of genetically modified strains focusing on understanding the basic features of abnormal neurodevelopment in ASD.</p>
<p>A relevant environmental risk factor known to recapitulate aspects of ASD pathology was extensively studied by Patterson and his collaborators (<xref ref-type="bibr" rid="B70">70</xref>). His group induced an acute inflammatory response on expectant pregnant rodents, causing maternal immune activation (MIA) leading to autistic phenotypes in the offspring (<xref ref-type="bibr" rid="B70">70</xref>). The mechanism for the development of autistic traits was later correlated with the release of IL-6, amongst other cytokine misbalances especially in CD4<sup>+</sup> T cells. The offspring from MIA models displayed general alteration of their immune profile and function, and interestingly, bone marrow transplantation of MIA-derived mice into irradiated control mice did not recapitulate the MIA phenotypes illustrating the importance of the peripheral system context in the immune system activation (<xref ref-type="bibr" rid="B71">71</xref>). Using CRE-induced models for local depletion of IL-6 receptors, Patterson's group showed that the placental IL-6 signaling is directly involved in fetal brain development and behavior and when IL-6 receptors were depleted in the placenta the MIA model had no effect on the offspring (<xref ref-type="bibr" rid="B72">72</xref>). Recent results from Cho et al. (<xref ref-type="bibr" rid="B73">73</xref>) also implicate the maternal interleukin-17a pathway in mice promoting autism-like phenotypes in the offspring. Their data suggest that therapeutic targeting of Th17 cells in susceptible pregnant mothers could potentially reduce the likelihood of bearing children with inflammation-induced ASD-like phenotypes (<xref ref-type="bibr" rid="B73">73</xref>).</p>
<p>Another relevant study proposed the hypothesis that blood marrow transplantations could improve the phenotype of mice with syndromic forms of ASD, such as RTT (<xref ref-type="bibr" rid="B74">74</xref>). The concept was based on the idea that healthy microglia would rescue RTT phenotypes in mouse models. While this is an appealing concept, several groups attempted to repeat the experiment using similar methodologies and the results have not been confirmed (<xref ref-type="bibr" rid="B75">75</xref>). Although microglia was not necessarily the culprit in the rescue of MeCP2-deficient phenotype, it is anticipated that this cell type plays an important role in the disease, particularly given its ability for synaptic pruning (<xref ref-type="bibr" rid="B76">76</xref>). Future studies will be crucial to consider the potential use of microglia replacement as a therapeutic strategy for ASD.</p>
<p>Mouse models lacking microglial fracktalkine receptor gene (<italic>CX3CR1</italic>) displayed increased microglial IL-1β resulting in an enhanced tauopathy, immature synapses throughout the cortex and connectivity imbalance with ASD-like behaviors (<xref ref-type="bibr" rid="B77">77</xref>). Blocking IL-1β/p38 MAPK pathways significantly improved the mouse phenotype and could be a promising therapeutic option (<xref ref-type="bibr" rid="B78">78</xref>). Interestingly, mouse models for RTT using MeCP2 KO mice crossed with mice with <italic>CX3CR1</italic> mutations recovered the MeCP2 deficient phenotype, suggesting that blocking the fracktalkine receptor is a possible therapeutic approach for RTT (<xref ref-type="bibr" rid="B79">79</xref>).</p>
<p>In 2011, a group led by Gail Mandel demonstrated the role for glia in the progression of RTT (<xref ref-type="bibr" rid="B53">53</xref>). Using MeCP2 KO animals and astrocyte-specific GFAP promoter controlling MeCP2 expression, they showed that astrocyte depletion of MeCP2 was detrimental to neurons in a non-cell autonomous fashion. Interestingly, the re-expression of MeCP2 in GFAP-driven cells was sufficient to rescue the RTT phenotype, and systemic delivery of MeCP2 was used as a therapeutic approach for female mouse models (<xref ref-type="bibr" rid="B80">80</xref>). Recent work demonstrated that MeCP2 expression in astrocytes affects glutamatergic synapses, highlighting the importance of astrocytes to ensure proper synaptic connectivity (<xref ref-type="bibr" rid="B81">81</xref>). Using primary rodent cells another group found that MeCP2-mutant astrocytes had an exaggerated inflammatory and oxidative stress response to LPS (Lipopolysaccharide) stimulation when compared to control cells, suggesting anti-inflammatory approaches for disease treatment (<xref ref-type="bibr" rid="B82">82</xref>).</p>
</sec>
<sec id="s6">
<title>Limitations of Current Models</title>
<p>All current <italic>in vivo</italic> and <italic>in vitro</italic> models have increased our overall mechanistic knowledge of ASD, however the complexity of idiopathic autism and the influence of epigenetic and environmental factors poses a challenge to modeling non-syndromic forms using rodent models. Furthermore, when attempting to study aspects of neuroinflammation, where specific cytokines can play a crucial role in the disorder and are species-specific (<xref ref-type="bibr" rid="B83">83</xref>), humanized models can be instrumental to obtain therapeutically relevant information. As iPSCs emerge as an important <italic>in vitro</italic> model for translational research, current limitations include the restricted complexity for cytokine signaling and the absence of body systemic interaction. Future improvements to iPSC technology will incorporate circulating blood and mature cell types to the current model systems.</p>
</sec>
<sec id="s7">
<title>Final Remarks</title>
<p>Increasing evidence supports the idea of immune system activation in ASD. iPSCs are crucial for a better understanding of complex polygenic diseases with heritable and sporadic forms, such as ASD in order to develop novel biomarkers and identify targets for future therapeutics (<xref ref-type="bibr" rid="B35">35</xref>). Deriving brain cells from iPSCs can in fact provide a unique opportunity to explore and identify early phenotypes in autism in opposition to secondary phenotypes that are a downstream consequence of the pathology. Moreover, iPSC technology is particularly valuable over the two most used research approaches to study and understand brain biology and pathology, namely post-mortem samples and mouse models. Post-mortem tissue has inherent limitations for studying a neurodevelopmental disease, mainly because it cannot be manipulated to test experimental hypotheses and provides only a brief snapshot in disease progression (<xref ref-type="bibr" rid="B84">84</xref>). Animal models can be genetically and pharmacologically manipulated, however, when it comes to behavioral, affective and cognitive changes, animal models may not always recapitulate the human phenotype (<xref ref-type="bibr" rid="B84">84</xref>, <xref ref-type="bibr" rid="B85">85</xref>). Ideally for a complex disorder, such as ASD one would take advantage of multiple models, using them as a base to build the background knowledge of the mechanism of the disorder, studying each individual player (i.e., neuron, glia) and as a complex niche (<italic>in vivo</italic>, in co-culture or brain organoid systems). The next step would be developing a high-throughput screening (HTS) system capable of identifying disease biomarkers and potentially detecting compounds that rescue a phenotype. Since ASD is a complex developmental disorder, studying iPSC-derived fetal-like cells is ideal for establishing a therapeutic approach as early as during gestation time (Figure <xref ref-type="fig" rid="F1">1</xref>). Recent research indicates a relevant role for the gut microbiota in autism (<xref ref-type="bibr" rid="B86">86</xref>), specially regarding inflammatory components (<xref ref-type="bibr" rid="B87">87</xref>–<xref ref-type="bibr" rid="B89">89</xref>). It would be interesting to see upcoming technologies, such as “organs-on-a-chip” that can integrate brain development with gut signaling to an <italic>in vitro</italic> platform.</p>
<p>iPSC technology is also a remarkable scientific tool to test compounds that could be used in the clinic for ASD individuals. The grouth factor IGF1 was first tested in RTT mouse models (<xref ref-type="bibr" rid="B90">90</xref>) and then iPSC from ASD patients (<xref ref-type="bibr" rid="B33">33</xref>, <xref ref-type="bibr" rid="B35">35</xref>) and it is now in clinical trials for syndromic and idiopathic forms of ASD<xref ref-type="fn" rid="fn0001"><sup>1</sup></xref><sup>,</sup>
<xref ref-type="fn" rid="fn0002"><sup>2</sup></xref><sup>,</sup>
<xref ref-type="fn" rid="fn0003"><sup>3</sup></xref><sup>,</sup>
<xref ref-type="fn" rid="fn0004"><sup>4</sup></xref><sup>,</sup>
<xref ref-type="fn" rid="fn0005"><sup>5</sup></xref> (<xref ref-type="bibr" rid="B91">91</xref>, <xref ref-type="bibr" rid="B92">92</xref>). The compound Luteolin (<xref ref-type="bibr" rid="B93">93</xref>) attenuates IL-6-mediated astrogliosis in human iPSC-derived neural aggregates and was proposed as a candidate preventive substance for maternal immune activation-induced abnormalities (<xref ref-type="bibr" rid="B94">94</xref>). Remarkably, Luteolin dietary intake improves ASD symptoms and reduces serum levels of TNF and IL-6 (<xref ref-type="bibr" rid="B95">95</xref>).</p>
<p>In summary, iPSC technology is an invaluable tool for asking questions about human-specific neuroinflammation mechanisms, such as the ones observed in syndromic and non-syndromic forms of ASD. Importantly, iPSCs can generate a platform for the discovery of new anti-inflammatory compounds that are tailored to the ASD-specific genetic background and neuropathological phenotypes and offer potential therapeutic options for both onset and progression of the disorder.</p>
</sec>
<sec id="s8">
<title>Author Contributions</title>
<p>All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.</p>
<sec>
<title>Conflict of Interest Statement</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
</sec>
</body>
<back>
<ack>
<p>The authors would like to acknowledge the support from the National Institutes of Health (NIH) grant number R03 MH115426-01A1 (MM).</p>
</ack>
<fn-group>
<fn id="fn0001">
<p><sup>1</sup><italic>A Pilot Treatment Study of Insulin-Like Growth Factor-1 (IGF-1) in Autism Spectrum Disorder</italic>. Available online at: <ext-link ext-link-type="uri" xlink:href="https://ClinicalTrials.gov/show/NCT01970345">https://ClinicalTrials.gov/show/NCT01970345</ext-link></p>
</fn>
<fn id="fn0002">
<p><sup>2</sup><italic>A Safety Study of NNZ-2566 in Patients With Fragile X Syndrome</italic>. Available online at: <ext-link ext-link-type="uri" xlink:href="https://ClinicalTrials.gov/show/NCT01894958">https://ClinicalTrials.gov/show/NCT01894958</ext-link></p>
</fn>
<fn id="fn0003">
<p><sup>3</sup><italic>Treatment of Rett Syndrome With Recombinant Human IGF-1</italic>. Available online at: <ext-link ext-link-type="uri" xlink:href="https://ClinicalTrials.gov/show/NCT01777542">https://ClinicalTrials.gov/show/NCT01777542</ext-link></p>
</fn>
<fn id="fn0004">
<p><sup>4</sup><italic>Clinical Trial in 22q13 Deletion Syndrome(Phelan-McDermid Syndrome)</italic>. Available online at: <ext-link ext-link-type="uri" xlink:href="https://ClinicalTrials.gov/show/NCT01525901">https://ClinicalTrials.gov/show/NCT01525901</ext-link></p>
</fn>
<fn id="fn0005">
<p><sup>5</sup><italic>Treatment of Rett Syndrome With rhIGF-1 (Mecasermin rDNA Injection)</italic>. Available online at: <ext-link ext-link-type="uri" xlink:href="https://ClinicalTrials.gov/show/NCT01253317">https://ClinicalTrials.gov/show/NCT01253317</ext-link></p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stoner</surname><given-names>R</given-names></name><name><surname>Chow</surname><given-names>ML</given-names></name><name><surname>Boyle</surname><given-names>MP</given-names></name><name><surname>Sunkin</surname><given-names>SM</given-names></name><name><surname>Mouton</surname><given-names>PR</given-names></name><name><surname>Roy</surname><given-names>S</given-names></name><etal></etal></person-group>. <article-title>Patches of disorganization in the neocortex of children with autism</article-title>. <source/>N Engl J Med. (<year>2014</year>) <volume>370</volume>:<fpage>1209</fpage>–<lpage>19</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1307491</pub-id><pub-id pub-id-type="pmid">24670167</pub-id></mixed-citation>
</ref>
<ref id="B2">
<label>2.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iossifov</surname><given-names>I</given-names></name><name><surname>Ronemus</surname><given-names>M</given-names></name><name><surname>Levy</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Hakker</surname><given-names>I</given-names></name><name><surname>Rosenbaum</surname><given-names>J</given-names></name><etal></etal></person-group>. <article-title>De novo gene disruptions in children on the autistic spectrum</article-title>. <source/>Neuron (<year>2012</year>) <volume>74</volume>:<fpage>285</fpage>–<lpage>99</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2012.04.009</pub-id><pub-id pub-id-type="pmid">22542183</pub-id></mixed-citation>
</ref>
<ref id="B3">
<label>3.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baio</surname><given-names>J</given-names></name><name><surname>Wiggins</surname><given-names>L</given-names></name><name><surname>Christensen</surname><given-names>DL</given-names></name><name><surname>Maenner</surname><given-names>MJ</given-names></name><name><surname>Daniels</surname><given-names>J</given-names></name><name><surname>Warren</surname><given-names>Z</given-names></name><etal></etal></person-group>. <article-title>Prevalence of autism spectrum disorder among children aged 8 years–autism and developmental disabilities monitoring network, 11 sites, United States, 2014</article-title>. <source/>MMWR Surveill Summ. (<year>2018</year>) <volume>67</volume>:<fpage>1</fpage>–<lpage>23</lpage>. <pub-id pub-id-type="doi">10.15585/mmwr.ss6706a1</pub-id><pub-id pub-id-type="pmid">29701730</pub-id></mixed-citation>
</ref>
<ref id="B4">
<label>4.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piven</surname><given-names>J</given-names></name><name><surname>Elison</surname><given-names>JT</given-names></name><name><surname>Zylka</surname><given-names>MJ</given-names></name></person-group>. <article-title>Toward a conceptual framework for early brain and behavior development in autism</article-title>. <source/>Mol Psychiatry (<year>2018</year>) <volume>23</volume>:<fpage>165</fpage>. <pub-id pub-id-type="doi">10.1038/mp.2017.212</pub-id><pub-id pub-id-type="pmid">29296026</pub-id></mixed-citation>
</ref>
<ref id="B5">
<label>5.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geschwind</surname><given-names>DH</given-names></name><name><surname>State</surname><given-names>MW</given-names></name></person-group>. <article-title>Gene hunting in autism spectrum disorder: on the path to precision medicine</article-title>. <source/>Lancet Neurol. (<year>2015</year>) <volume>14</volume>:<fpage>1109</fpage>–<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1016/S1474-4422(15)00044-7</pub-id><pub-id pub-id-type="pmid">25891009</pub-id></mixed-citation>
</ref>
<ref id="B6">
<label>6.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sebat</surname><given-names>J</given-names></name><name><surname>Lakshmi</surname><given-names>B</given-names></name><name><surname>Malhotra</surname><given-names>D</given-names></name><name><surname>Troge</surname><given-names>J</given-names></name><name><surname>Lese-Martin</surname><given-names>C</given-names></name><name><surname>Walsh</surname><given-names>T</given-names></name><etal></etal></person-group>. <article-title>Strong association of de novo copy number mutations with autism</article-title>. <source/>Science (<year>2007</year>) <volume>316</volume>:<fpage>445</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1126/science.1138659</pub-id><pub-id pub-id-type="pmid">17363630</pub-id></mixed-citation>
</ref>
<ref id="B7">
<label>7.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Devlin</surname><given-names>B</given-names></name><name><surname>Scherer</surname><given-names>SW</given-names></name></person-group>. <article-title>Genetic architecture in autism spectrum disorder</article-title>. <source/>Curr Opin Genet Dev. (<year>2012</year>) <volume>22</volume>:<fpage>229</fpage>–<lpage>37</lpage>. <pub-id pub-id-type="doi">10.1016/j.gde.2012.03.002</pub-id><pub-id pub-id-type="pmid">22463983</pub-id></mixed-citation>
</ref>
<ref id="B8">
<label>8.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de la Torre-Ubieta</surname><given-names>L</given-names></name><name><surname>Won</surname><given-names>H</given-names></name><name><surname>Stein</surname><given-names>JL</given-names></name><name><surname>Geschwind</surname><given-names>DH</given-names></name></person-group>
<article-title>Advancing the understanding of autism disease mechanisms through genetics</article-title>. <source/>Nat Med. (<year>2016</year>) <volume>22</volume>:<fpage>345</fpage>–<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1038/nm.4071</pub-id><pub-id pub-id-type="pmid">27050589</pub-id></mixed-citation>
</ref>
<ref id="B9">
<label>9.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Volk</surname><given-names>HE</given-names></name><name><surname>Kerin</surname><given-names>T</given-names></name><name><surname>Lurmann</surname><given-names>F</given-names></name><name><surname>Hertz-Picciotto</surname><given-names>I</given-names></name><name><surname>McConnell</surname><given-names>R</given-names></name><name><surname>Campbell</surname><given-names>DB</given-names></name></person-group>. <article-title>Autism spectrum disorder: interaction of air pollution with the MET receptor tyrosine kinase gene</article-title>. <source/>Epidemiology (<year>2014</year>) <volume>25</volume>:<fpage>44</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1097/EDE.0000000000000030</pub-id><pub-id pub-id-type="pmid">24240654</pub-id></mixed-citation>
</ref>
<ref id="B10">
<label>10.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Onore</surname><given-names>C</given-names></name><name><surname>Careaga</surname><given-names>M</given-names></name><name><surname>Ashwood</surname><given-names>P</given-names></name></person-group>. <article-title>The role of immune dysfunction in the pathophysiology of autism</article-title>. <source/>Brain Behav Immun. (<year>2012</year>) <volume>26</volume>:<fpage>383</fpage>–<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbi.2011.08.007</pub-id><pub-id pub-id-type="pmid">21906670</pub-id></mixed-citation>
</ref>
<ref id="B11">
<label>11.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scott</surname><given-names>O</given-names></name><name><surname>Shi</surname><given-names>D</given-names></name><name><surname>Andriashek</surname><given-names>D</given-names></name><name><surname>Clark</surname><given-names>B</given-names></name><name><surname>Goez</surname><given-names>HR</given-names></name></person-group>. <article-title>Clinical clues for autoimmunity and neuroinflammation in patients with autistic regression</article-title>. <source/>Dev Med Child Neurol. (<year>2017</year>) <volume>59</volume>:<fpage>947</fpage>–<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1111/dmcn.13432</pub-id><pub-id pub-id-type="pmid">28383115</pub-id></mixed-citation>
</ref>
<ref id="B12">
<label>12.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mazur-Kolecka</surname><given-names>B</given-names></name><name><surname>Cohen</surname><given-names>IL</given-names></name><name><surname>Gonzalez</surname><given-names>M</given-names></name><name><surname>Jenkins</surname><given-names>EC</given-names></name><name><surname>Kaczmarski</surname><given-names>W</given-names></name><name><surname>Brown</surname><given-names>WT</given-names></name><etal></etal></person-group>. <article-title>Autoantibodies against neuronal progenitors in sera from children with autism</article-title>. <source/>Brain Dev. (<year>2014</year>) <volume>36</volume>:<fpage>322</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.braindev.2013.04.015</pub-id><pub-id pub-id-type="pmid">23838310</pub-id></mixed-citation>
</ref>
<ref id="B13">
<label>13.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Estes</surname><given-names>ML</given-names></name><name><surname>McAllister</surname><given-names>AK</given-names></name></person-group>. <article-title>Immune mediators in the brain and peripheral tissues in autism spectrum disorder</article-title>. <source/>Nat Rev Neurosci. (<year>2015</year>) <volume>16</volume>:<fpage>469</fpage>–<lpage>86</lpage>. <pub-id pub-id-type="doi">10.1038/nrn3978</pub-id><pub-id pub-id-type="pmid">26189694</pub-id></mixed-citation>
</ref>
<ref id="B14">
<label>14.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lanz</surname><given-names>TA</given-names></name><name><surname>Guilmette</surname><given-names>E</given-names></name><name><surname>Gosink</surname><given-names>MM</given-names></name><name><surname>Fischer</surname><given-names>JE</given-names></name><name><surname>Fitzgerald</surname><given-names>LW</given-names></name><name><surname>Stephenson</surname><given-names>DT</given-names></name><etal></etal></person-group>. <article-title>Transcriptomic analysis of genetically defined autism candidate genes reveals common mechanisms of action</article-title>. <source/>Mol Autism (<year>2013</year>) <volume>4</volume>:<fpage>45</fpage>. <pub-id pub-id-type="doi">10.1186/2040-2392-4-45</pub-id><pub-id pub-id-type="pmid">24238429</pub-id></mixed-citation>
</ref>
<ref id="B15">
<label>15.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>S</given-names></name><name><surname>Ellis</surname><given-names>SE</given-names></name><name><surname>Ashar</surname><given-names>FN</given-names></name><name><surname>Moes</surname><given-names>A</given-names></name><name><surname>Bader</surname><given-names>JS</given-names></name><name><surname>Zhan</surname><given-names>J</given-names></name><etal></etal></person-group>. <article-title>Transcriptome analysis reveals dysregulation of innate immune response genes and neuronal activity-dependent genes in autism</article-title>. <source/>Nat Commun. (<year>2014</year>) <volume>5</volume>:<fpage>5748</fpage>. <pub-id pub-id-type="doi">10.1038/ncomms6748</pub-id><pub-id pub-id-type="pmid">25494366</pub-id></mixed-citation>
</ref>
<ref id="B16">
<label>16.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ansel</surname><given-names>A</given-names></name><name><surname>Rosenzweig</surname><given-names>JP</given-names></name><name><surname>Zisman</surname><given-names>PD</given-names></name><name><surname>Melamed</surname><given-names>M</given-names></name><name><surname>Gesundheit</surname><given-names>B</given-names></name></person-group>. <article-title>Variation in gene expression in autism spectrum disorders: an extensive review of transcriptomic studies</article-title>. <source/>Front Neurosci. (<year>2016</year>) <volume>10</volume>:<fpage>601</fpage>. <pub-id pub-id-type="doi">10.3389/fnins.2016.00601</pub-id><pub-id pub-id-type="pmid">28105001</pub-id></mixed-citation>
</ref>
<ref id="B17">
<label>17.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Voineagu</surname><given-names>I</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Johnston</surname><given-names>P</given-names></name><name><surname>Lowe</surname><given-names>JK</given-names></name><name><surname>Tian</surname><given-names>Y</given-names></name><name><surname>Horvath</surname><given-names>S</given-names></name><etal></etal></person-group>. <article-title>Transcriptomic analysis of autistic brain reveals convergent molecular pathology</article-title>. <source/>Nature (<year>2011</year>) <volume>474</volume>:<fpage>380</fpage>–<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1038/nature10110</pub-id><pub-id pub-id-type="pmid">21614001</pub-id></mixed-citation>
</ref>
<ref id="B18">
<label>18.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imamura</surname><given-names>R</given-names></name><name><surname>Matsumoto</surname><given-names>K</given-names></name></person-group>. <article-title>Hepatocyte growth factor in physiology and infectious diseases</article-title>. <source/>Cytokine (<year>2017</year>) <volume>98</volume>:<fpage>97</fpage>–<lpage>106</lpage>. <pub-id pub-id-type="doi">10.1016/j.cyto.2016.12.025</pub-id><pub-id pub-id-type="pmid">28094206</pub-id></mixed-citation>
</ref>
<ref id="B19">
<label>19.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campbell</surname><given-names>DB</given-names></name><name><surname>Sutcliffe</surname><given-names>JS</given-names></name><name><surname>Ebert</surname><given-names>PJ</given-names></name><name><surname>Militerni</surname><given-names>R</given-names></name><name><surname>Bravaccio</surname><given-names>C</given-names></name><name><surname>Trillo</surname><given-names>S</given-names></name><etal></etal></person-group>. <article-title>A genetic variant that disrupts MET transcription is associated with autism</article-title>. <source/>Proc Natl Acad Sci USA. (<year>2006</year>) <volume>103</volume>:<fpage>16834</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0605296103</pub-id><pub-id pub-id-type="pmid">17053076</pub-id></mixed-citation>
</ref>
<ref id="B20">
<label>20.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>Y</given-names></name><name><surname>Huentelman</surname><given-names>M</given-names></name><name><surname>Smith</surname><given-names>C</given-names></name><name><surname>Qiu</surname><given-names>S</given-names></name></person-group>. <article-title>MET receptor tyrosine kinase as an autism genetic risk factor</article-title>. <source/>Int Rev Neurobiol. (<year>2013</year>) <volume>113</volume>:<fpage>135</fpage>–<lpage>65</lpage>. <pub-id pub-id-type="doi">10.1016/B978-0-12-418700-9.00005-8</pub-id><pub-id pub-id-type="pmid">24290385</pub-id></mixed-citation>
</ref>
<ref id="B21">
<label>21.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warren</surname><given-names>RP</given-names></name><name><surname>Burger</surname><given-names>RA</given-names></name><name><surname>Odell</surname><given-names>D</given-names></name><name><surname>Torres</surname><given-names>AR</given-names></name><name><surname>Warren</surname><given-names>WL</given-names></name></person-group>. <article-title>Decreased plasma concentrations of the C4B complement protein in autism</article-title>. <source/>Arch Pediatr Adolesc Med. (<year>1994</year>) <volume>148</volume>:<fpage>180</fpage>–<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1001/archpedi.1994.02170020066011</pub-id><pub-id pub-id-type="pmid">8118537</pub-id></mixed-citation>
</ref>
<ref id="B22">
<label>22.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Odell</surname><given-names>D</given-names></name><name><surname>Maciulis</surname><given-names>A</given-names></name><name><surname>Cutler</surname><given-names>A</given-names></name><name><surname>Warren</surname><given-names>L</given-names></name><name><surname>McMahon</surname><given-names>WM</given-names></name><name><surname>Coon</surname><given-names>H</given-names></name><etal></etal></person-group>. <article-title>Confirmation of the association of the C4B null allelle in autism</article-title>. <source/>Hum Immunol. (<year>2005</year>) <volume>66</volume>:<fpage>140</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1016/j.humimm.2004.11.002</pub-id><pub-id pub-id-type="pmid">15694999</pub-id></mixed-citation>
</ref>
<ref id="B23">
<label>23.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gorelik</surname><given-names>A</given-names></name><name><surname>Sapir</surname><given-names>T</given-names></name><name><surname>Haffner-Krausz</surname><given-names>R</given-names></name><name><surname>Olender</surname><given-names>T</given-names></name><name><surname>Woodruff</surname><given-names>TM</given-names></name><name><surname>Reiner</surname><given-names>O</given-names></name></person-group>. <article-title>Developmental activities of the complement pathway in migrating neurons</article-title>. <source/>Nat Commun. (<year>2017</year>) <volume>8</volume>:<fpage>15096</fpage>. <pub-id pub-id-type="doi">10.1038/ncomms15096</pub-id><pub-id pub-id-type="pmid">28462915</pub-id></mixed-citation>
</ref>
<ref id="B24">
<label>24.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campbell</surname><given-names>DB</given-names></name><name><surname>D'Oronzio</surname><given-names>R</given-names></name><name><surname>Garbett</surname><given-names>K</given-names></name><name><surname>Ebert</surname><given-names>PJ</given-names></name><name><surname>Mirnics</surname><given-names>K</given-names></name><name><surname>Levitt</surname><given-names>P</given-names></name><etal></etal></person-group>. <article-title>Disruption of cerebral cortex MET signaling in autism spectrum disorder</article-title>. <source/>Ann Neurol. (<year>2007</year>) <volume>62</volume>:<fpage>243</fpage>–<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1002/ana.21180</pub-id><pub-id pub-id-type="pmid">17696172</pub-id></mixed-citation>
</ref>
<ref id="B25">
<label>25.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Croen</surname><given-names>LA</given-names></name><name><surname>Qian</surname><given-names>Y</given-names></name><name><surname>Ashwood</surname><given-names>P</given-names></name><name><surname>Daniels</surname><given-names>JL</given-names></name><name><surname>Fallin</surname><given-names>D</given-names></name><name><surname>Schendel</surname><given-names>D</given-names></name><etal></etal></person-group>. <article-title>Family history of immune conditions and autism spectrum and developmental disorders: findings from the study to explore early development</article-title>. <source/>Autism Res. (<year>2018</year>). <pub-id pub-id-type="doi">10.1002/aur.1979</pub-id><pub-id pub-id-type="pmid">30095240</pub-id></mixed-citation>
</ref>
<ref id="B26">
<label>26.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keil</surname><given-names>A</given-names></name><name><surname>Daniels</surname><given-names>JL</given-names></name><name><surname>Forssen</surname><given-names>U</given-names></name><name><surname>Hultman</surname><given-names>C</given-names></name><name><surname>Cnattingius</surname><given-names>S</given-names></name><name><surname>Söderberg</surname><given-names>KC</given-names></name><etal></etal></person-group>. <article-title>Parental autoimmune diseases associated with autism spectrum disorders in offspring</article-title>. <source/>Epidemiology (<year>2010</year>) <volume>21</volume>:<fpage>805</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1097/EDE.0b013e3181f26e3f</pub-id><pub-id pub-id-type="pmid">20798635</pub-id></mixed-citation>
</ref>
<ref id="B27">
<label>27.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atladóttir</surname><given-names>HO</given-names></name><name><surname>Pedersen</surname><given-names>MG</given-names></name><name><surname>Thorsen</surname><given-names>P</given-names></name><name><surname>Mortensen</surname><given-names>PB</given-names></name><name><surname>Deleuran</surname><given-names>B</given-names></name><name><surname>Eaton</surname><given-names>WW</given-names></name><etal></etal></person-group>. <article-title>Association of family history of autoimmune diseases and autism spectrum disorders</article-title>. <source/>Pediatrics (<year>2009</year>) <volume>124</volume>:<fpage>687</fpage>–<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1542/peds.2008-2445</pub-id><pub-id pub-id-type="pmid">19581261</pub-id></mixed-citation>
</ref>
<ref id="B28">
<label>28.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knuesel</surname><given-names>I</given-names></name><name><surname>Chicha</surname><given-names>L</given-names></name><name><surname>Britschgi</surname><given-names>M</given-names></name><name><surname>Schobel</surname><given-names>SA</given-names></name><name><surname>Bodmer</surname><given-names>M</given-names></name><name><surname>Hellings</surname><given-names>JA</given-names></name><etal></etal></person-group>. <article-title>Maternal immune activation and abnormal brain development across CNS disorders</article-title>. <source/>Nat Rev Neurol. (<year>2014</year>) <volume>10</volume>:<fpage>643</fpage>–<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1038/nrneurol.2014.187</pub-id><pub-id pub-id-type="pmid">25311587</pub-id></mixed-citation>
</ref>
<ref id="B29">
<label>29.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goines</surname><given-names>P</given-names></name><name><surname>Van de Water</surname><given-names>J</given-names></name></person-group>. <article-title>The immune system's role in the biology of autism</article-title>. <source/>Curr Opin Neurol. (<year>2010</year>) <volume>23</volume>:<fpage>111</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1097/WCO.0b013e3283373514</pub-id><pub-id pub-id-type="pmid">20160651</pub-id></mixed-citation>
</ref>
<ref id="B30">
<label>30.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eftekharian</surname><given-names>MM</given-names></name><name><surname>Ghafouri-Fard</surname><given-names>S</given-names></name><name><surname>Noroozi</surname><given-names>R</given-names></name><name><surname>Omrani</surname><given-names>MD</given-names></name><name><surname>Arsang-Jang</surname><given-names>S</given-names></name><name><surname>Ganji</surname><given-names>M</given-names></name><etal></etal></person-group>. <article-title>Cytokine profile in autistic patients</article-title>. <source/>Cytokine (<year>2018</year>) <volume>108</volume>:<fpage>120</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.cyto.2018.03.034</pub-id><pub-id pub-id-type="pmid">29602155</pub-id></mixed-citation>
</ref>
<ref id="B31">
<label>31.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ross</surname><given-names>CA</given-names></name><name><surname>Akimov</surname><given-names>SS</given-names></name></person-group>. <article-title>Human-induced pluripotent stem cells: potential for neurodegenerative diseases</article-title>. <source/>Hum Mol Genet. (<year>2014</year>) <volume>23</volume>:<fpage>R17</fpage>–<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/ddu204</pub-id><pub-id pub-id-type="pmid">24824217</pub-id></mixed-citation>
</ref>
<ref id="B32">
<label>32.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lancaster</surname><given-names>MA</given-names></name><name><surname>Renner</surname><given-names>M</given-names></name><name><surname>Martin</surname><given-names>CA</given-names></name><name><surname>Wenzel</surname><given-names>D</given-names></name><name><surname>Bicknell</surname><given-names>LS</given-names></name><name><surname>Hurles</surname><given-names>ME</given-names></name><etal></etal></person-group>. <article-title>Cerebral organoids model human brain development and microcephaly</article-title>. <source/>Nature (<year>2013</year>) <volume>501</volume>:<fpage>373</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1038/nature12517</pub-id><pub-id pub-id-type="pmid">23995685</pub-id></mixed-citation>
</ref>
<ref id="B33">
<label>33.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marchetto</surname><given-names>MC</given-names></name><name><surname>Carromeu</surname><given-names>C</given-names></name><name><surname>Acab</surname><given-names>A</given-names></name><name><surname>Yu</surname><given-names>D</given-names></name><name><surname>Yeo</surname><given-names>GW</given-names></name><name><surname>Mu</surname><given-names>Y</given-names></name><etal></etal></person-group>. <article-title>A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells</article-title>. <source/>Cell (<year>2010</year>) <volume>143</volume>:<fpage>527</fpage>–<lpage>39</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2010.10.016</pub-id><pub-id pub-id-type="pmid">21074045</pub-id></mixed-citation>
</ref>
<ref id="B34">
<label>34.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mariani</surname><given-names>J</given-names></name><name><surname>Coppola</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Abyzov</surname><given-names>A</given-names></name><name><surname>Provini</surname><given-names>L</given-names></name><name><surname>Tomasini</surname><given-names>L</given-names></name><etal></etal></person-group>. <article-title>FOXG1-dependent dysregulation of GABA/glutamate neuron differentiation in autism spectrum disorders</article-title>. <source/>Cell (<year>2015</year>) <volume>162</volume>:<fpage>375</fpage>–<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2015.06.034</pub-id><pub-id pub-id-type="pmid">26186191</pub-id></mixed-citation>
</ref>
<ref id="B35">
<label>35.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marchetto</surname><given-names>MC</given-names></name><name><surname>Belinson</surname><given-names>H</given-names></name><name><surname>Tian</surname><given-names>Y</given-names></name><name><surname>Freitas</surname><given-names>BC</given-names></name><name><surname>Fu</surname><given-names>C</given-names></name><name><surname>Vadodaria</surname><given-names>K</given-names></name><etal></etal></person-group>. <article-title>Altered proliferation and networks in neural cells derived from idiopathic autistic individuals</article-title>. <source/>Mol Psychiatry (<year>2017</year>) <volume>22</volume>:<fpage>820</fpage>–<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1038/mp.2016.95</pub-id><pub-id pub-id-type="pmid">27378147</pub-id></mixed-citation>
</ref>
<ref id="B36">
<label>36.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shcheglovitov</surname><given-names>A</given-names></name><name><surname>Shcheglovitova</surname><given-names>O</given-names></name><name><surname>Yazawa</surname><given-names>M</given-names></name><name><surname>Portmann</surname><given-names>T</given-names></name><name><surname>Shu</surname><given-names>R</given-names></name><name><surname>Sebastiano</surname><given-names>V</given-names></name><etal></etal></person-group>. <article-title>SHANK3 and IGF1 restore synaptic deficits in neurons from 22q13 deletion syndrome patients</article-title>. <source/>Nature (<year>2013</year>) <volume>503</volume>:<fpage>267</fpage>–<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1038/nature12618</pub-id><pub-id pub-id-type="pmid">24132240</pub-id></mixed-citation>
</ref>
<ref id="B37">
<label>37.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nageshappa</surname><given-names>S</given-names></name><name><surname>Carromeu</surname><given-names>C</given-names></name><name><surname>Trujillo</surname><given-names>CA</given-names></name><name><surname>Mesci</surname><given-names>P</given-names></name><name><surname>Espuny-Camacho</surname><given-names>I</given-names></name><name><surname>Pasciuto</surname><given-names>E</given-names></name><etal></etal></person-group>. <article-title>Altered neuronal network and rescue in a human MECP2 duplication model</article-title>. <source/>Mol Psychiatry (<year>2016</year>) <volume>21</volume>:<fpage>178</fpage>–<lpage>88</lpage>. <pub-id pub-id-type="doi">10.1038/mp.2015.128</pub-id><pub-id pub-id-type="pmid">26347316</pub-id></mixed-citation>
</ref>
<ref id="B38">
<label>38.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheridan</surname><given-names>SD</given-names></name><name><surname>Theriault</surname><given-names>KM</given-names></name><name><surname>Reis</surname><given-names>SA</given-names></name><name><surname>Zhou</surname><given-names>F</given-names></name><name><surname>Madison</surname><given-names>JM</given-names></name><name><surname>Daheron</surname><given-names>L</given-names></name><etal></etal></person-group>. <article-title>Epigenetic characterization of the FMR1 gene and aberrant neurodevelopment in human induced pluripotent stem cell models of fragile X syndrome</article-title>. <source/>PLoS ONE (<year>2011</year>) <volume>6</volume>:<fpage>e26203</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0026203</pub-id><pub-id pub-id-type="pmid">22022567</pub-id></mixed-citation>
</ref>
<ref id="B39">
<label>39.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheung</surname><given-names>AY</given-names></name><name><surname>Horvath</surname><given-names>LM</given-names></name><name><surname>Grafodatskaya</surname><given-names>D</given-names></name><name><surname>Pasceri</surname><given-names>P</given-names></name><name><surname>Weksberg</surname><given-names>R</given-names></name><name><surname>Hotta</surname><given-names>A</given-names></name><etal></etal></person-group>. <article-title>Isolation of MECP2-null Rett Syndrome patient hiPS cells and isogenic controls through X-chromosome inactivation</article-title>. <source/>Hum Mol Genet. (<year>2011</year>) <volume>20</volume>:<fpage>2103</fpage>–<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/ddr093</pub-id><pub-id pub-id-type="pmid">21372149</pub-id></mixed-citation>
</ref>
<ref id="B40">
<label>40.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paşca</surname><given-names>SP</given-names></name><name><surname>Portmann</surname><given-names>T</given-names></name><name><surname>Voineagu</surname><given-names>I</given-names></name><name><surname>Yazawa</surname><given-names>M</given-names></name><name><surname>Shcheglovitov</surname><given-names>A</given-names></name><name><surname>Paşca</surname><given-names>AM</given-names></name><etal></etal></person-group>. <article-title>Using iPSC-derived neurons to uncover cellular phenotypes associated with Timothy syndrome</article-title>. <source/>Nat Med. (<year>2011</year>) <volume>17</volume>:<fpage>1657</fpage>–<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1038/nm.2576</pub-id><pub-id pub-id-type="pmid">22120178</pub-id></mixed-citation>
</ref>
<ref id="B41">
<label>41.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Griesi-Oliveira</surname><given-names>K</given-names></name><name><surname>Acab</surname><given-names>A</given-names></name><name><surname>Gupta</surname><given-names>AR</given-names></name><name><surname>Sunaga</surname><given-names>DY</given-names></name><name><surname>Chailangkarn</surname><given-names>T</given-names></name><name><surname>Nicol</surname><given-names>X</given-names></name><etal></etal></person-group>. <article-title>Modeling non-syndromic autism and the impact of TRPC6 disruption in human neurons</article-title>. <source/>Mol Psychiatry (<year>2015</year>) <volume>20</volume>:<fpage>1350</fpage>–<lpage>65</lpage>. <pub-id pub-id-type="doi">10.1038/mp.2014.141</pub-id><pub-id pub-id-type="pmid">25385366</pub-id></mixed-citation>
</ref>
<ref id="B42">
<label>42.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>X</given-names></name><name><surname>Yeung</surname><given-names>HT</given-names></name><name><surname>Lai</surname><given-names>KO</given-names></name></person-group>. <article-title>Application of human-induced pluripotent stem cells (hiPSCs) to study synaptopathy of neurodevelopmental disorders</article-title>. <source/>Dev Neurobiol. (<year>2018</year>). <pub-id pub-id-type="doi">10.1002/dneu.22644</pub-id><pub-id pub-id-type="pmid">30304570</pub-id></mixed-citation>
</ref>
<ref id="B43">
<label>43.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Russo</surname><given-names>FB</given-names></name><name><surname>Freitas</surname><given-names>BC</given-names></name><name><surname>Pignatari</surname><given-names>GC</given-names></name><name><surname>Fernandes</surname><given-names>IR</given-names></name><name><surname>Sebat</surname><given-names>J</given-names></name><name><surname>Muotri</surname><given-names>AR</given-names></name><etal></etal></person-group>. <article-title>Modeling the interplay between neurons and astrocytes in autism using human induced pluripotent stem cells</article-title>. <source/>Biol Psychiatry (<year>2018</year>) <volume>83</volume>:<fpage>569</fpage>–<lpage>78</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2017.09.021</pub-id><pub-id pub-id-type="pmid">29129319</pub-id></mixed-citation>
</ref>
<ref id="B44">
<label>44.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Chauhan</surname><given-names>A</given-names></name><name><surname>Sheikh</surname><given-names>AM</given-names></name><name><surname>Patil</surname><given-names>S</given-names></name><name><surname>Chauhan</surname><given-names>V</given-names></name><name><surname>Li</surname><given-names>XM</given-names></name><etal></etal></person-group>. <article-title>Elevated immune response in the brain of autistic patients</article-title>. <source/>J Neuroimmunol. (<year>2009</year>) <volume>207</volume>:<fpage>111</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.jneuroim.2008.12.002</pub-id><pub-id pub-id-type="pmid">19157572</pub-id></mixed-citation>
</ref>
<ref id="B45">
<label>45.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deverman</surname><given-names>BE</given-names></name><name><surname>Patterson</surname><given-names>PH</given-names></name></person-group>. <article-title>Cytokines and CNS development</article-title>. <source/>Neuron (<year>2009</year>) <volume>64</volume>:<fpage>61</fpage>–<lpage>78</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2009.09.002</pub-id><pub-id pub-id-type="pmid">19840550</pub-id></mixed-citation>
</ref>
<ref id="B46">
<label>46.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Acab</surname><given-names>A</given-names></name><name><surname>Muotri</surname><given-names>AR</given-names></name></person-group>. <article-title>The use of induced pluripotent stem cell technology to advance autism research and treatment</article-title>. <source/>Neurotherapeutics (<year>2015</year>) <volume>12</volume>:<fpage>534</fpage>–<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1007/s13311-015-0354-x</pub-id><pub-id pub-id-type="pmid">25851569</pub-id></mixed-citation>
</ref>
<ref id="B47">
<label>47.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amir</surname><given-names>RE</given-names></name><name><surname>Van den Veyver</surname><given-names>IB</given-names></name><name><surname>Wan</surname><given-names>M</given-names></name><name><surname>Tran</surname><given-names>CQ</given-names></name><name><surname>Francke</surname><given-names>U</given-names></name><name><surname>Zoghbi</surname><given-names>HY</given-names></name></person-group>. <article-title>Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2</article-title>. <source/>Nat Genet. (<year>1999</year>) <volume>23</volume>:<fpage>185</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1038/13810</pub-id><pub-id pub-id-type="pmid">10508514</pub-id></mixed-citation>
</ref>
<ref id="B48">
<label>48.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>W</given-names></name><name><surname>Gandal</surname><given-names>MJ</given-names></name><name><surname>Ehrlichman</surname><given-names>RS</given-names></name><name><surname>Siegel</surname><given-names>SJ</given-names></name><name><surname>Carlson</surname><given-names>GC</given-names></name></person-group>. <article-title>MeCP2<sup>+/−</sup> mouse model of RTT reproduces auditory phenotypes associated with Rett syndrome and replicate select EEG endophenotypes of autism spectrum disorder</article-title>. <source/>Neurobiol Dis. (<year>2012</year>) <volume>46</volume>:<fpage>88</fpage>–<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1016/j.nbd.2011.12.048</pub-id><pub-id pub-id-type="pmid">22249109</pub-id></mixed-citation>
</ref>
<ref id="B49">
<label>49.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chahrour</surname><given-names>M</given-names></name><name><surname>Zoghbi</surname><given-names>HY</given-names></name></person-group>. <article-title>The story of Rett syndrome: from clinic to neurobiology</article-title>. <source/>Neuron (<year>2007</year>) <volume>56</volume>:<fpage>422</fpage>–<lpage>37</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2007.10.001</pub-id><pub-id pub-id-type="pmid">17988628</pub-id></mixed-citation>
</ref>
<ref id="B50">
<label>50.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schanen</surname><given-names>C</given-names></name><name><surname>Francke</surname><given-names>U</given-names></name></person-group>. <article-title>A severely affected male born into a Rett syndrome kindred supports X-linked inheritance and allows extension of the exclusion map</article-title>. <source/>Am J Hum Genet. (<year>1998</year>) <volume>63</volume>:<fpage>267</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1086/301932</pub-id><pub-id pub-id-type="pmid">9637791</pub-id></mixed-citation>
</ref>
<ref id="B51">
<label>51.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Villard</surname><given-names>L</given-names></name><name><surname>Kpebe</surname><given-names>A</given-names></name><name><surname>Cardoso</surname><given-names>C</given-names></name><name><surname>Chelly</surname><given-names>PJ</given-names></name><name><surname>Tardieu</surname><given-names>PM</given-names></name><name><surname>Fontes</surname><given-names>M</given-names></name></person-group>. <article-title>Two affected boys in a Rett syndrome family: clinical and molecular findings</article-title>. <source/>Neurology (<year>2000</year>) <volume>55</volume>:<fpage>1188</fpage>–<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1212/WNL.55.8.1188</pub-id><pub-id pub-id-type="pmid">11071498</pub-id></mixed-citation>
</ref>
<ref id="B52">
<label>52.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chahrour</surname><given-names>M</given-names></name><name><surname>Jung</surname><given-names>SY</given-names></name><name><surname>Shaw</surname><given-names>C</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Wong</surname><given-names>ST</given-names></name><name><surname>Qin</surname><given-names>J</given-names></name><etal></etal></person-group>. <article-title>MeCP2, a key contributor to neurological disease, activates and represses transcription</article-title>. <source/>Science (<year>2008</year>) <volume>320</volume>:<fpage>1224</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1126/science.1153252</pub-id><pub-id pub-id-type="pmid">18511691</pub-id></mixed-citation>
</ref>
<ref id="B53">
<label>53.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lioy</surname><given-names>DT</given-names></name><name><surname>Garg</surname><given-names>SK</given-names></name><name><surname>Monaghan</surname><given-names>CE</given-names></name><name><surname>Raber</surname><given-names>J</given-names></name><name><surname>Foust</surname><given-names>KD</given-names></name><name><surname>Kaspar</surname><given-names>BK</given-names></name><etal></etal></person-group>. <article-title>A role for glia in the progression of Rett's syndrome</article-title>. <source/>Nature (<year>2011</year>) <volume>475</volume>:<fpage>497</fpage>–<lpage>500</lpage>. <pub-id pub-id-type="doi">10.1038/nature10214</pub-id><pub-id pub-id-type="pmid">21716289</pub-id></mixed-citation>
</ref>
<ref id="B54">
<label>54.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>EC</given-names></name><name><surname>Zhong</surname><given-names>X</given-names></name><name><surname>Mohamed</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>R</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Dong</surname><given-names>Q</given-names></name><etal></etal></person-group>. <article-title>Mutant astrocytes differentiated from Rett syndrome patients-specific iPSCs have adverse effects on wild-type neurons</article-title>. <source/>Hum Mol Genet. (<year>2014</year>) <volume>23</volume>:<fpage>2968</fpage>–<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/ddu008</pub-id><pub-id pub-id-type="pmid">24419315</pub-id></mixed-citation>
</ref>
<ref id="B55">
<label>55.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Theoharides</surname><given-names>TC</given-names></name><name><surname>Athanassiou</surname><given-names>M</given-names></name><name><surname>Panagiotidou</surname><given-names>S</given-names></name><name><surname>Doyle</surname><given-names>R</given-names></name></person-group>. <article-title>Dysregulated brain immunity and neurotrophin signaling in Rett syndrome and autism spectrum disorders</article-title>. <source/>J Neuroimmunol. (<year>2015</year>) <volume>279</volume>:<fpage>33</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.jneuroim.2014.12.003</pub-id><pub-id pub-id-type="pmid">25669997</pub-id></mixed-citation>
</ref>
<ref id="B56">
<label>56.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maezawa</surname><given-names>I</given-names></name><name><surname>Calafiore</surname><given-names>M</given-names></name><name><surname>Wulff</surname><given-names>H</given-names></name><name><surname>Jin</surname><given-names>LW</given-names></name></person-group>. <article-title>Does microglial dysfunction play a role in autism and Rett syndrome?</article-title>
<source/>Neuron Glia Biol. (<year>2011</year>) <volume>7</volume>:<fpage>85</fpage>–<lpage>97</lpage>. <pub-id pub-id-type="doi">10.1017/S1740925X1200004X</pub-id><pub-id pub-id-type="pmid">22717189</pub-id></mixed-citation>
</ref>
<ref id="B57">
<label>57.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maezawa</surname><given-names>I</given-names></name><name><surname>Jin</surname><given-names>LW</given-names></name></person-group>. <article-title>Rett syndrome microglia damage dendrites and synapses by the elevated release of glutamate</article-title>. <source/>J Neurosci. (<year>2010</year>) <volume>30</volume>:<fpage>5346</fpage>–<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.5966-09.2010</pub-id><pub-id pub-id-type="pmid">20392956</pub-id></mixed-citation>
</ref>
<ref id="B58">
<label>58.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amenduni</surname><given-names>M</given-names></name><name><surname>De Filippis</surname><given-names>R</given-names></name><name><surname>Cheung</surname><given-names>AY</given-names></name><name><surname>Disciglio</surname><given-names>V</given-names></name><name><surname>Epistolato</surname><given-names>MC</given-names></name><name><surname>Ariani</surname><given-names>F</given-names></name><etal></etal></person-group>. <article-title>iPS cells to model CDKL5-related disorders</article-title>. <source/>Eur J Hum Genet. (<year>2011</year>) <volume>19</volume>:<fpage>1246</fpage>–<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1038/ejhg.2011.131</pub-id><pub-id pub-id-type="pmid">21750574</pub-id></mixed-citation>
</ref>
<ref id="B59">
<label>59.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Zhu</surname><given-names>YC</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Miao</surname><given-names>S</given-names></name><name><surname>Zheng</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><etal></etal></person-group>. <article-title>CDKL5, a protein associated with rett syndrome, regulates neuronal morphogenesis via Rac1 signaling</article-title>. <source/>J Neurosci. (<year>2010</year>) <volume>30</volume>:<fpage>12777</fpage>–<lpage>86</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.1102-10.2010</pub-id><pub-id pub-id-type="pmid">20861382</pub-id></mixed-citation>
</ref>
<ref id="B60">
<label>60.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ricciardi</surname><given-names>S</given-names></name><name><surname>Ungaro</surname><given-names>F</given-names></name><name><surname>Hambrock</surname><given-names>M</given-names></name><name><surname>Rademacher</surname><given-names>N</given-names></name><name><surname>Stefanelli</surname><given-names>G</given-names></name><name><surname>Brambilla</surname><given-names>D</given-names></name><etal></etal></person-group>. <article-title>CDKL5 ensures excitatory synapse stability by reinforcing NGL-1-PSD95 interaction in the postsynaptic compartment and is impaired in patient iPSC-derived neurons</article-title>. <source/>Nat Cell Biol. (<year>2012</year>) <volume>14</volume>:<fpage>911</fpage>–<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1038/ncb2566</pub-id><pub-id pub-id-type="pmid">22922712</pub-id></mixed-citation>
</ref>
<ref id="B61">
<label>61.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cronk</surname><given-names>JC</given-names></name><name><surname>Derecki</surname><given-names>NC</given-names></name><name><surname>Ji</surname><given-names>E</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Lampano</surname><given-names>AE</given-names></name><name><surname>Smirnov</surname><given-names>I</given-names></name><etal></etal></person-group>. <article-title>Methyl-CpG binding protein 2 regulates microglia and macrophage gene expression in response to inflammatory stimuli</article-title>. <source/>Immunity (<year>2015</year>) <volume>42</volume>:<fpage>679</fpage>–<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2015.03.013</pub-id><pub-id pub-id-type="pmid">25902482</pub-id></mixed-citation>
</ref>
<ref id="B62">
<label>62.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leoncini</surname><given-names>S</given-names></name><name><surname>De Felice</surname><given-names>C</given-names></name><name><surname>Signorini</surname><given-names>C</given-names></name><name><surname>Zollo</surname><given-names>G</given-names></name><name><surname>Cortelazzo</surname><given-names>A</given-names></name><name><surname>Durand</surname><given-names>T</given-names></name><etal></etal></person-group>. <article-title>Cytokine dysregulation in MECP2- and CDKL5-related rett syndrome: relationships with aberrant redox homeostasis, inflammation, and omega-3 PUFAs</article-title>. <source/>Oxid Med Cell Longev. (<year>2015</year>) <volume>2015</volume>:<fpage>421624</fpage>. <pub-id pub-id-type="doi">10.1155/2015/421624</pub-id><pub-id pub-id-type="pmid">26236424</pub-id></mixed-citation>
</ref>
<ref id="B63">
<label>63.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Urbach</surname><given-names>A</given-names></name><name><surname>Bar-Nur</surname><given-names>O</given-names></name><name><surname>Daley</surname><given-names>GQ</given-names></name><name><surname>Benvenisty</surname><given-names>N</given-names></name></person-group>. <article-title>Differential modeling of fragile X syndrome by human embryonic stem cells and induced pluripotent stem cells</article-title>. <source/>Cell Stem Cell (<year>2010</year>) <volume>6</volume>:<fpage>407</fpage>–<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1016/j.stem.2010.04.005</pub-id><pub-id pub-id-type="pmid">20452313</pub-id></mixed-citation>
</ref>
<ref id="B64">
<label>64.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bassell</surname><given-names>GJ</given-names></name><name><surname>Warren</surname><given-names>ST</given-names></name></person-group>. <article-title>Fragile X syndrome: loss of local mRNA regulation alters synaptic development and function</article-title>. <source/>Neuron (<year>2008</year>) <volume>60</volume>:<fpage>201</fpage>–<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2008.10.004</pub-id><pub-id pub-id-type="pmid">18957214</pub-id></mixed-citation>
</ref>
<ref id="B65">
<label>65.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Connor</surname><given-names>RM</given-names></name><name><surname>Stone</surname><given-names>EF</given-names></name><name><surname>Wayne</surname><given-names>CR</given-names></name><name><surname>Marcinkevicius</surname><given-names>EV</given-names></name><name><surname>Ulgherait</surname><given-names>M</given-names></name><name><surname>Delventhal</surname><given-names>R</given-names></name><etal></etal></person-group>. <article-title>A Drosophila model of Fragile X syndrome exhibits defects in phagocytosis by innate immune cells</article-title>. <source/>J Cell Biol. (<year>2017</year>) <volume>216</volume>:<fpage>595</fpage>–<lpage>605</lpage>. <pub-id pub-id-type="doi">10.1083/jcb.201607093</pub-id><pub-id pub-id-type="pmid">28223318</pub-id></mixed-citation>
</ref>
<ref id="B66">
<label>66.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sunamura</surname><given-names>N</given-names></name><name><surname>Iwashita</surname><given-names>S</given-names></name><name><surname>Enomoto</surname><given-names>K</given-names></name><name><surname>Kadoshima</surname><given-names>T</given-names></name><name><surname>Isono</surname><given-names>F</given-names></name></person-group>. <article-title>Loss of the fragile X mental retardation protein causes aberrant differentiation in human neural progenitor cells</article-title>. <source/>Sci Rep. (<year>2018</year>) <volume>8</volume>:<fpage>11585</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-018-30025-4</pub-id><pub-id pub-id-type="pmid">30072797</pub-id></mixed-citation>
</ref>
<ref id="B67">
<label>67.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pacey</surname><given-names>LK</given-names></name><name><surname>Guan</surname><given-names>S</given-names></name><name><surname>Tharmalingam</surname><given-names>S</given-names></name><name><surname>Thomsen</surname><given-names>C</given-names></name><name><surname>Hampson</surname><given-names>DR</given-names></name></person-group>. <article-title>Persistent astrocyte activation in the fragile X mouse cerebellum</article-title>. <source/>Brain Behav. (<year>2015</year>) <volume>5</volume>:<fpage>e00400</fpage>. <pub-id pub-id-type="doi">10.1002/brb3.400</pub-id><pub-id pub-id-type="pmid">26516618</pub-id></mixed-citation>
</ref>
<ref id="B68">
<label>68.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krasovska</surname><given-names>V</given-names></name><name><surname>Doering</surname><given-names>LC</given-names></name></person-group>. <article-title>Regulation of IL-6 secretion by astrocytes via TLR4 in the Fragile X mouse model</article-title>. <source/>Front Mol Neurosci. (<year>2018</year>) <volume>11</volume>:<fpage>272</fpage>. <pub-id pub-id-type="doi">10.3389/fnmol.2018.00272</pub-id><pub-id pub-id-type="pmid">30123107</pub-id></mixed-citation>
</ref>
<ref id="B69">
<label>69.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boland</surname><given-names>MJ</given-names></name><name><surname>Nazor</surname><given-names>KL</given-names></name><name><surname>Tran</surname><given-names>HT</given-names></name><name><surname>Szücs</surname><given-names>A</given-names></name><name><surname>Lynch</surname><given-names>CL</given-names></name><name><surname>Paredes</surname><given-names>R</given-names></name><etal></etal></person-group>. <article-title>Molecular analyses of neurogenic defects in a human pluripotent stem cell model of fragile X syndrome</article-title>. <source/>Brain (<year>2017</year>) <volume>140</volume>:<fpage>582</fpage>–<lpage>98</lpage>. <pub-id pub-id-type="doi">10.1093/brain/aww357</pub-id><pub-id pub-id-type="pmid">28137726</pub-id></mixed-citation>
</ref>
<ref id="B70">
<label>70.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malkova</surname><given-names>NV</given-names></name><name><surname>Yu</surname><given-names>CZ</given-names></name><name><surname>Hsiao</surname><given-names>EY</given-names></name><name><surname>Moore</surname><given-names>MJ</given-names></name><name><surname>Patterson</surname><given-names>PH</given-names></name></person-group>. <article-title>Maternal immune activation yields offspring displaying mouse versions of the three core symptoms of autism</article-title>. <source/>Brain Behav Immun. (<year>2012</year>) <volume>26</volume>:<fpage>607</fpage>–<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbi.2012.01.011</pub-id><pub-id pub-id-type="pmid">22310922</pub-id></mixed-citation>
</ref>
<ref id="B71">
<label>71.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsiao</surname><given-names>EY</given-names></name><name><surname>Patterson</surname><given-names>PH</given-names></name></person-group>. <article-title>Placental regulation of maternal-fetal interactions and brain development</article-title>. <source/>Dev Neurobiol. (<year>2012</year>) <volume>72</volume>:<fpage>1317</fpage>–<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1002/dneu.22045</pub-id><pub-id pub-id-type="pmid">22753006</pub-id></mixed-citation>
</ref>
<ref id="B72">
<label>72.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>WL</given-names></name><name><surname>Hsiao</surname><given-names>EY</given-names></name><name><surname>Yan</surname><given-names>Z</given-names></name><name><surname>Mazmanian</surname><given-names>SK</given-names></name><name><surname>Patterson</surname><given-names>PH</given-names></name></person-group>. <article-title>The placental interleukin-6 signaling controls fetal brain development and behavior</article-title>. <source/>Brain Behav Immun. (<year>2017</year>) <volume>62</volume>:<fpage>11</fpage>–<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbi.2016.11.007</pub-id><pub-id pub-id-type="pmid">27838335</pub-id></mixed-citation>
</ref>
<ref id="B73">
<label>73.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>GB</given-names></name><name><surname>Yim</surname><given-names>YS</given-names></name><name><surname>Wong</surname><given-names>H</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Kim</surname><given-names>SV</given-names></name><etal></etal></person-group>. <article-title>The maternal interleukin-17a pathway in mice promotes autism-like phenotypes in offspring</article-title>. <source/>Science (<year>2016</year>) <volume>351</volume>:<fpage>933</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1126/science.aad0314</pub-id><pub-id pub-id-type="pmid">26822608</pub-id></mixed-citation>
</ref>
<ref id="B74">
<label>74.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Derecki</surname><given-names>NC</given-names></name><name><surname>Cronk</surname><given-names>JC</given-names></name><name><surname>Lu</surname><given-names>Z</given-names></name><name><surname>Xu</surname><given-names>E</given-names></name><name><surname>Abbott</surname><given-names>SB</given-names></name><name><surname>Guyenet</surname><given-names>PG</given-names></name><etal></etal></person-group>. <article-title>Wild-type microglia arrest pathology in a mouse model of Rett syndrome</article-title>. <source/>Nature (<year>2012</year>) <volume>484</volume>:<fpage>105</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1038/nature10907</pub-id><pub-id pub-id-type="pmid">22425995</pub-id></mixed-citation>
</ref>
<ref id="B75">
<label>75.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><etal></etal></person-group>
<article-title>Wild-type microglia do not reverse pathology in mouse models of Rett syndrome</article-title>. <source/>Nature (<year>2015</year>) <volume>521</volume>:<fpage>E1</fpage>–<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1038/nature14444</pub-id><pub-id pub-id-type="pmid">25993969</pub-id></mixed-citation>
</ref>
<ref id="B76">
<label>76.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schafer</surname><given-names>DP</given-names></name><name><surname>Heller</surname><given-names>CT</given-names></name><name><surname>Gunner</surname><given-names>G</given-names></name><name><surname>Heller</surname><given-names>M</given-names></name><name><surname>Gordon</surname><given-names>C</given-names></name><name><surname>Hammond</surname><given-names>T</given-names></name><etal></etal></person-group>. <article-title>Microglia contribute to circuit defects in Mecp2 null mice independent of microglia-specific loss of Mecp2 expression</article-title>. <source/>Elife (<year>2016</year>) <volume>5</volume>:<fpage>e15224</fpage>. <pub-id pub-id-type="doi">10.7554/eLife.15224</pub-id><pub-id pub-id-type="pmid">27458802</pub-id></mixed-citation>
</ref>
<ref id="B77">
<label>77.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Limatola</surname><given-names>C</given-names></name><name><surname>Ransohoff</surname><given-names>RM</given-names></name></person-group>. <article-title>Modulating neurotoxicity through CX3CL1/CX3CR1 signaling</article-title>. <source/>Front Cell Neurosci. (<year>2014</year>) <volume>8</volume>:<fpage>229</fpage>. <pub-id pub-id-type="doi">10.3389/fncel.2014.00229</pub-id><pub-id pub-id-type="pmid">25152714</pub-id></mixed-citation>
</ref>
<ref id="B78">
<label>78.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>G</given-names></name><name><surname>Jay</surname><given-names>TR</given-names></name><name><surname>Bhatta</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>KW</given-names></name><name><surname>Jung</surname><given-names>S</given-names></name><etal></etal></person-group>. <article-title>Opposing effects of membrane-anchored CX3CL1 on amyloid and tau pathologies via the p38 MAPK pathway</article-title>. <source/>J Neurosci. (<year>2014</year>) <volume>34</volume>:<fpage>12538</fpage>–<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.0853-14.2014</pub-id><pub-id pub-id-type="pmid">25209291</pub-id></mixed-citation>
</ref>
<ref id="B79">
<label>79.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horiuchi</surname><given-names>M</given-names></name><name><surname>Smith</surname><given-names>L</given-names></name><name><surname>Maezawa</surname><given-names>I</given-names></name><name><surname>Jin</surname><given-names>LW</given-names></name></person-group>. <article-title>CX3CR1 ablation ameliorates motor and respiratory dysfunctions and improves survival of a Rett syndrome mouse model</article-title>. <source/>Brain Behav Immun. (<year>2017</year>) <volume>60</volume>:<fpage>106</fpage>–<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbi.2016.02.014</pub-id><pub-id pub-id-type="pmid">26883520</pub-id></mixed-citation>
</ref>
<ref id="B80">
<label>80.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garg</surname><given-names>SK</given-names></name><name><surname>Lioy</surname><given-names>DT</given-names></name><name><surname>Cheval</surname><given-names>H</given-names></name><name><surname>McGann</surname><given-names>JC</given-names></name><name><surname>Bissonnette</surname><given-names>JM</given-names></name><name><surname>Murtha</surname><given-names>MJ</given-names></name><etal></etal></person-group>. <article-title>Systemic delivery of MeCP2 rescues behavioral and cellular deficits in female mouse models of Rett syndrome</article-title>. <source/>J Neurosci. (<year>2013</year>) <volume>33</volume>:<fpage>13612</fpage>–<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.1854-13.2013</pub-id><pub-id pub-id-type="pmid">23966684</pub-id></mixed-citation>
</ref>
<ref id="B81">
<label>81.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rakela</surname><given-names>B</given-names></name><name><surname>Brehm</surname><given-names>P</given-names></name><name><surname>Mandel</surname><given-names>G</given-names></name></person-group>. <article-title>Astrocytic modulation of excitatory synaptic signaling in a mouse model of Rett syndrome</article-title>. <source/>Elife (<year>2018</year>) <volume>7</volume>:<fpage>e31629</fpage>. <pub-id pub-id-type="doi">10.7554/eLife.31629</pub-id><pub-id pub-id-type="pmid">29313799</pub-id></mixed-citation>
</ref>
<ref id="B82">
<label>82.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nance</surname><given-names>E</given-names></name><name><surname>Kambhampati</surname><given-names>SP</given-names></name><name><surname>Smith</surname><given-names>ES</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Singh</surname><given-names>S</given-names></name><etal></etal></person-group>. <article-title>Dendrimer-mediated delivery of N-acetyl cysteine to microglia in a mouse model of Rett syndrome</article-title>. <source/>J Neuroinflammation (<year>2017</year>) <volume>14</volume>:<fpage>252</fpage>. <pub-id pub-id-type="doi">10.1186/s12974-017-1004-5</pub-id><pub-id pub-id-type="pmid">29258545</pub-id></mixed-citation>
</ref>
<ref id="B83">
<label>83.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mestas</surname><given-names>J</given-names></name><name><surname>Hughes</surname><given-names>CC</given-names></name></person-group>
<article-title>Of mice and not men: differences between mouse and human immunology</article-title>. <source/>J Immunol. (<year>2004</year>) <volume>172</volume>:<fpage>2731</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.172.5.2731</pub-id><pub-id pub-id-type="pmid">14978070</pub-id></mixed-citation>
</ref>
<ref id="B84">
<label>84.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Habela</surname><given-names>CW</given-names></name><name><surname>Song</surname><given-names>H</given-names></name><name><surname>Ming</surname><given-names>GL</given-names></name></person-group>. <article-title>Modeling synaptogenesis in schizophrenia and autism using human iPSC derived neurons</article-title>. <source/>Mol Cell Neurosci. (<year>2016</year>) <volume>73</volume>:<fpage>52</fpage>–<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1016/j.mcn.2015.12.002</pub-id><pub-id pub-id-type="pmid">26655799</pub-id></mixed-citation>
</ref>
<ref id="B85">
<label>85.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>CA</given-names></name><name><surname>Watson</surname><given-names>DJ</given-names></name><name><surname>Fone</surname><given-names>KC</given-names></name></person-group>. <article-title>Animal models of schizophrenia</article-title>. <source/>Br J Pharmacol. (<year>2011</year>) <volume>164</volume>:<fpage>1162</fpage>–<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1111/j.1476-5381.2011.01386.x</pub-id><pub-id pub-id-type="pmid">21449915</pub-id></mixed-citation>
</ref>
<ref id="B86">
<label>86.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsiao</surname><given-names>EY</given-names></name><name><surname>McBride</surname><given-names>SW</given-names></name><name><surname>Hsien</surname><given-names>S</given-names></name><name><surname>Sharon</surname><given-names>G</given-names></name><name><surname>Hyde</surname><given-names>ER</given-names></name><name><surname>McCue</surname><given-names>T</given-names></name><etal></etal></person-group>. <article-title>Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders</article-title>. <source/>Cell (<year>2013</year>) <volume>155</volume>:<fpage>1451</fpage>–<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2013.11.024</pub-id><pub-id pub-id-type="pmid">24315484</pub-id></mixed-citation>
</ref>
<ref id="B87">
<label>87.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharon</surname><given-names>G</given-names></name><name><surname>Sampson</surname><given-names>TR</given-names></name><name><surname>Geschwind</surname><given-names>DH</given-names></name><name><surname>Mazmanian</surname><given-names>SK</given-names></name></person-group>. <article-title>The central nervous system and the gut microbiome</article-title>. <source/>Cell (<year>2016</year>) <volume>167</volume>:<fpage>915</fpage>–<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2016.10.027</pub-id><pub-id pub-id-type="pmid">27814521</pub-id></mixed-citation>
</ref>
<ref id="B88">
<label>88.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Round</surname><given-names>JL</given-names></name><name><surname>Mazmanian</surname><given-names>SK</given-names></name></person-group>. <article-title>The gut microbiota shapes intestinal immune responses during health and disease</article-title>. <source/>Nat Rev Immunol. (<year>2009</year>) <volume>9</volume>:<fpage>313</fpage>–<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1038/nri2515</pub-id><pub-id pub-id-type="pmid">19343057</pub-id></mixed-citation>
</ref>
<ref id="B89">
<label>89.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doenyas</surname><given-names>C</given-names></name></person-group>. <article-title>Gut microbiota, inflammation, and probiotics on neural development in autism spectrum disorder</article-title>. <source/>Neuroscience (<year>2018</year>) <volume>374</volume>:<fpage>271</fpage>–<lpage>86</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroscience.2018.01.060</pub-id><pub-id pub-id-type="pmid">29427656</pub-id></mixed-citation>
</ref>
<ref id="B90">
<label>90.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tropea</surname><given-names>D</given-names></name><name><surname>Giacometti</surname><given-names>E</given-names></name><name><surname>Wilson</surname><given-names>NR</given-names></name><name><surname>Beard</surname><given-names>C</given-names></name><name><surname>McCurry</surname><given-names>C</given-names></name><name><surname>Fu</surname><given-names>DD</given-names></name><etal></etal></person-group>. <article-title>Partial reversal of Rett Syndrome-like symptoms in MeCP2 mutant mice</article-title>. <source/>Proc Natl Acad Sci USA. (<year>2009</year>) <volume>106</volume>:<fpage>2029</fpage>–<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0812394106</pub-id><pub-id pub-id-type="pmid">19208815</pub-id></mixed-citation>
</ref>
<ref id="B91">
<label>91.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khwaja</surname><given-names>OS</given-names></name><name><surname>Ho</surname><given-names>E</given-names></name><name><surname>Barnes</surname><given-names>KV</given-names></name><name><surname>O'Leary</surname><given-names>HM</given-names></name><name><surname>Pereira</surname><given-names>LM</given-names></name><name><surname>Finkelstein</surname><given-names>Y</given-names></name><etal></etal></person-group>. <article-title>Safety, pharmacokinetics, and preliminary assessment of efficacy of mecasermin (recombinant human IGF-1) for the treatment of Rett syndrome</article-title>. <source/>Proc Natl Acad Sci USA. (<year>2014</year>) <volume>111</volume>:<fpage>4596</fpage>–<lpage>601</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1311141111</pub-id><pub-id pub-id-type="pmid">24623853</pub-id></mixed-citation>
</ref>
<ref id="B92">
<label>92.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kolevzon</surname><given-names>A</given-names></name><name><surname>Bush</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>AT</given-names></name><name><surname>Halpern</surname><given-names>D</given-names></name><name><surname>Frank</surname><given-names>Y</given-names></name><name><surname>Grodberg</surname><given-names>D</given-names></name><etal></etal></person-group>. <article-title>A pilot controlled trial of insulin-like growth factor-1 in children with Phelan-McDermid syndrome</article-title>. <source/>Mol Autism (<year>2014</year>) <volume>5</volume>:<fpage>54</fpage>. <pub-id pub-id-type="doi">10.1186/2040-2392-5-54</pub-id><pub-id pub-id-type="pmid">25685306</pub-id></mixed-citation>
</ref>
<ref id="B93">
<label>93.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeon</surname><given-names>IH</given-names></name><name><surname>Kim</surname><given-names>HS</given-names></name><name><surname>Kang</surname><given-names>HJ</given-names></name><name><surname>Lee</surname><given-names>HS</given-names></name><name><surname>Jeong</surname><given-names>SI</given-names></name><name><surname>Kim</surname><given-names>SJ</given-names></name><etal></etal></person-group>. <article-title>Anti-inflammatory and antipruritic effects of luteolin from Perilla (<italic>P. frutescens</italic> L.) leaves</article-title>. <source/>Molecules (<year>2014</year>) <volume>19</volume>:<fpage>6941</fpage>–<lpage>51</lpage>. <pub-id pub-id-type="doi">10.3390/molecules19066941</pub-id><pub-id pub-id-type="pmid">24871572</pub-id></mixed-citation>
</ref>
<ref id="B94">
<label>94.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zuiki</surname><given-names>M</given-names></name><name><surname>Chiyonobu</surname><given-names>T</given-names></name><name><surname>Yoshida</surname><given-names>M</given-names></name><name><surname>Maeda</surname><given-names>H</given-names></name><name><surname>Yamashita</surname><given-names>S</given-names></name><name><surname>Kidowaki</surname><given-names>S</given-names></name><etal></etal></person-group>. <article-title>Luteolin attenuates interleukin-6-mediated astrogliosis in human iPSC-derived neural aggregates: a candidate preventive substance for maternal immune activation-induced abnormalities</article-title>. <source/>Neurosci Lett. (<year>2017</year>) <volume>653</volume>:<fpage>296</fpage>–<lpage>301</lpage>. <pub-id pub-id-type="doi">10.1016/j.neulet.2017.06.004</pub-id><pub-id pub-id-type="pmid">28595950</pub-id></mixed-citation>
</ref>
<ref id="B95">
<label>95.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsilioni</surname><given-names>I</given-names></name><name><surname>Taliou</surname><given-names>A</given-names></name><name><surname>Francis</surname><given-names>K</given-names></name><name><surname>Theoharides</surname><given-names>TC</given-names></name></person-group>. <article-title>Children with autism spectrum disorders, who improved with a luteolin-containing dietary formulation, show reduced serum levels of TNF and IL-6</article-title>. <source/>Transl Psychiatry (<year>2015</year>) <volume>5</volume>:<fpage>e647</fpage>. <pub-id pub-id-type="doi">10.1038/tp.2015.142</pub-id><pub-id pub-id-type="pmid">26418275</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>